Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Stephen Mandel Initiates New Position in Horizon Pharma PLC (HZNP), Up 200% This Year

Page 1 of 2

Stephen Mandel’s Lone Pine Capital acquired 8.35 million shares of Horizon Pharma PLC (NASDAQ:HZNP) on July 17, 2015, according to a recent 13G filing made by the hedge fund. The Tiger Cub now owns 5.4% of the common shares of the biopharmaceutical company.Auspex Pharmaceuticals, Inc. (ASPX)

Stephen Mandel is one of the many Tiger Cubs with their own firms now, having worked for Julian Robertson until 1997, when he left to establish Lone Pine Capital. According to Forbes’ Real-Time net worth estimator, Mr. Mandel has a net worth of $2.3 billion as of July 29, ranking him 284 in the list of billionaires within the United States. He is known for his excellent stock picking skills and follows a “bottom up” approach to selecting investments. At the end of the first quarter, Lone Pine Capital reported a public equity portfolio worth $26.42 billion, with the holdings of the investment manager being primarily in the information technology sector, followed by the consumer discretionary and finance sectors. His top ten stock holdings account for 43.32% of his overall portfolio value. Priceline Group Inc (NASDAQ:PCLN) was the top equity investment of Lone Pine Capital at the end of the first quarter, as it held 1.33 million shares worth $1.55 billion of the online travel services provider.

Stephen Mandel
Stephen Mandel
Lone Pine Capital

Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole. These small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Moreover, since the beginning of forward testing from August 2012, the strategy worked just as our research predicted, outperforming the market every year and returning 123% over the last 34 months, which is more than 66 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

Horizon Pharma PLC (NASDAQ:HZNP) is a specialty biopharmaceutical company that targets unmet medical requirements, with its portfolio including medications for inflammation, arthritis, and orphan diseases. The medical company was formed when Horizon Pharma acquired Vidara Therapeutics International plc in September 2014, with the resultant company being called Horizon Pharma PLC (NASDAQ:HZNP). Shares of Horizon are up by just under 200% year-to-date. The shares of Horizon Pharma closed 6.06% higher on July 28 after the company announced a partnership with Fox Chase Cancer Center, for the purposes of treating cancer. Jeffrey Sherman, Chief Medical Officer and executive vice-president of research and development at Horizon said, “Through this research, our goal is to gain a better understanding of the potential for ACTIMMUNE along with PD-1 and PD-L1 inhibitors in different patient populations and disease areas.”

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!